Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease
- PMID: 1350805
- DOI: 10.1016/0140-6736(92)91196-f
Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease
Erratum in
- Lancet 1992 Jul 4;340(8810):64. Maranganore, DM [corrected to Maraganore, DM]
Abstract
The pathogenesis of Parkinson's disease may be influenced by genetic and environmental factors. Cytochrome P450 mono-oxygenases help to protect against toxic environmental compounds and individual variations in cytochrome P450 expression might, therefore, influence susceptibility to environmentally linked diseases. The frequency of mutant CYP2D6 alleles was studied in 229 patients with Parkinson's disease and 720 controls. Individuals with a metabolic defect in the cytochrome P450 CYP2D6-debrisoquine hydroxylase gene with the poor metaboliser phenotype had a 2.54-fold (95% Cl 1.51-4.28) increased risk of Parkinson's disease. Determination of CYP2D6 phenotype and genotype may help to identify those at greatest risk of Parkinson's disease and may also help to identify the environmental or metabolic agents involved in the pathogenesis of this disease.
Comment in
-
Parkinson's disease, but not Alzheimer's disease, Lewy body variant associated with mutant alleles at cytochrome P450 gene.Lancet. 1994 Sep 17;344(8925):815. doi: 10.1016/s0140-6736(94)92370-1. Lancet. 1994. PMID: 7916091 No abstract available.
Similar articles
-
Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease.J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):911-3. doi: 10.1136/jnnp.57.8.911. J Neurol Neurosurg Psychiatry. 1994. PMID: 8057112 Free PMC article.
-
CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.Mov Disord. 1995 May;10(3):277-8. doi: 10.1002/mds.870100307. Mov Disord. 1995. PMID: 7651442
-
Mutant debrisoquine hydroxylation genes in Parkinson's disease.Lancet. 1992 Apr 25;339(8800):1017-8. doi: 10.1016/0140-6736(92)90537-d. Lancet. 1992. PMID: 1349052
-
Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism.Adv Neurol. 1996;69:61-72. Adv Neurol. 1996. PMID: 8615186 Review. No abstract available.
-
Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.DNA Cell Biol. 1996 Apr;15(4):273-80. doi: 10.1089/dna.1996.15.273. DNA Cell Biol. 1996. PMID: 8639263 Review.
Cited by
-
Combinations of susceptible genotypes and individual responses to toxicants.Environ Health Perspect. 1997 Jun;105 Suppl 4(Suppl 4):755-8. doi: 10.1289/ehp.97105s4755. Environ Health Perspect. 1997. PMID: 9255557 Free PMC article. Review.
-
Nuclear complementation restores mtDNA levels in cultured cells from a patient with mtDNA depletion.Am J Hum Genet. 1993 Sep;53(3):663-9. Am J Hum Genet. 1993. PMID: 8394647 Free PMC article.
-
Clinical pharmacokinetic considerations in the elderly. An update.Clin Pharmacokinet. 1997 Oct;33(4):302-12. doi: 10.2165/00003088-199733040-00005. Clin Pharmacokinet. 1997. PMID: 9342505 Review.
-
Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease.J Biol Chem. 2013 Feb 8;288(6):4436-51. doi: 10.1074/jbc.M112.402123. Epub 2012 Dec 20. J Biol Chem. 2013. PMID: 23258538 Free PMC article.
-
Hypersusceptibility to chemicals: risk factors for neurological disease?J Neurol Neurosurg Psychiatry. 1993 Sep;56(9):943-6. doi: 10.1136/jnnp.56.9.943. J Neurol Neurosurg Psychiatry. 1993. PMID: 8410033 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical